255 related articles for article (PubMed ID: 17707139)
1. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
[TBL] [Abstract][Full Text] [Related]
2. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
3. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO).
Wallack MK; McNally K; Michaelides M; Bash J; Bartolucci A; Siegler H; Balch C; Wanebo H
Am Surg; 1986 Mar; 52(3):148-51. PubMed ID: 3513682
[TBL] [Abstract][Full Text] [Related]
5. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
Smith CL; Dunbar PR; Mirza F; Palmowski MJ; Shepherd D; Gilbert SC; Coulie P; Schneider J; Hoffman E; Hawkins R; Harris AL; Cerundolo V
Int J Cancer; 2005 Jan; 113(2):259-66. PubMed ID: 15386406
[TBL] [Abstract][Full Text] [Related]
6. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
[TBL] [Abstract][Full Text] [Related]
8. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
[TBL] [Abstract][Full Text] [Related]
9. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
[TBL] [Abstract][Full Text] [Related]
10. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
11. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
[TBL] [Abstract][Full Text] [Related]
12. Active specific immunotherapy with vaccinia melanoma oncolysate.
Wallack MK; Scoggin SD; Sivanandham M
Mt Sinai J Med; 1992 May; 59(3):227-33. PubMed ID: 1318507
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
[TBL] [Abstract][Full Text] [Related]
14. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
[No Abstract] [Full Text] [Related]
15. Xenovaccinotherapy for melanoma.
Seledtsov VI; Shishkov AA; Surovtseva MA; Samarin DM; Seledtsova GV; Niza NA; Seledtsov DV
Eur J Dermatol; 2006; 16(6):655-61. PubMed ID: 17229606
[TBL] [Abstract][Full Text] [Related]
16. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
[TBL] [Abstract][Full Text] [Related]
17. Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs.
Fukumoto S; Tamaki Y; Okamura M; Bannai H; Yokoyama N; Suzuki T; Igarashi I; Suzuki H; Xuan X
Vaccine; 2007 Jan; 25(7):1334-41. PubMed ID: 17055131
[TBL] [Abstract][Full Text] [Related]
18. Improvement in disease-free survival of melanoma patients in conjunction with serologic response in a phase Ia/Ib Southeastern Cancer Study Group trial of vaccinia melanoma oncolysate.
Wallack MK; Bash J; Bartolucci A
Am Surg; 1989 Apr; 55(4):243-7. PubMed ID: 2650593
[TBL] [Abstract][Full Text] [Related]
19. [Passive immunotherapy of melanoma].
Jotereau F; Labarriere N; Gervois N; Pandolfino MC; Dreno B
Bull Cancer; 2003 Jul; 90(7):583-6. PubMed ID: 12957798
[TBL] [Abstract][Full Text] [Related]
20. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
